Myriad Genetics Expands Genomics Footprint For Precision Medicine On Mason Municipal Campus

Myriad Genetics, one of Mason’s leading biohealth companies specializing in precision medicine, recently completed an expansion doubling current R&D lab space and capacity. This expansion, located in the lower level of the City’s Municipal Center, secures the genomics operations for GeneSight in Mason long-term. Believed to be the only CAP Accredited CLIA Certified Lab located on a municipal campus in the United States, it is a testament to the creative approach regularly applied by the City of Mason, which is driving renewed investment by med tech and companies so hotly courted by the West Coast.

GeneSight is a flagship Myriad product and is a pharmacogenomic test that analyzes how genes may affect medication outcomes. Results can inform doctors about how a person may break down or respond to certain medications commonly prescribed to treat depression, anxiety, ADHD, and other psychiatric conditions.

Predicated on the increasing demand for mental health diagnostics and solutions in recent years, the 5,000-square-foot buildout provides additional infrastructure critical to scale up capacity and provide business continuity. This past fall, the company had a milestone achievement testing over 2 million patients and is on track for continued exponential growth in the coming years. This growth is clear validation of the expanded adoption of pharmacogenetic testing as a data driven approach with actionable information in treatment decisions.

Mason initially recruited Assurex Health to the Municipal campus in 2010 to secure their growth and in 2016 Myriad Genetics acquired Assurex. Since that time, the company has expanded six times within the City.

A top priority to the City of Mason is to attract and grow precision medicine companies like Myriad Genetics. The continued re-investment and re-commitment to the City by companies like Myriad Genetics provides a compelling story of successful partnership to similar companies looking to site a new R&D lab in a collaborative location.

To learn more about Myriad’s GeneSight test, visit genesight.com